GERON CORPORATION (NASDAQ:GERN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Compensatory Arrangements of Certain Officers
On February 8, 2017, the Compensation Committee of the Board of
Directors (the Board) of Geron Corporation (the Company)
approved: (a) annual base salaries for 2017 and (b) cash
performance bonuses for 2016 for the following principal
financial officer and named executive officers of the Company:
| Name and Current Position | Salary | Salary | ||
| Increase | Increase | Base | Cash | |
| (%) | ($) | Salary | Bonus | |
|
Olivia K. Bloom, Executive Vice President, Finance, Chief Financial Officer and Treasurer |
5.9% | $22,800 | $410,000 | $179,500 |
|
Melissa Kelly Behrs, Executive Vice President, Business Development and Portfolio Alliance Management |
3.5% | $13,100 | $386,500 | $173,100 |
|
Andrew J. Grethlein, Ph.D., Executive Vice President, Development and Technical Operations |
3.5% | $14,100 | $416,200 | $186,400 |
|
Stephen N. Rosenfield, J.D., Executive Vice President, General Counsel and Corporate Secretary |
3.5% | $11,640 | $342,640(1) | $153,400 |
(1) Reflects Mr. Rosenfields continued employment by the Company
at 80% time.
On February 9, 2017, the Board approved the annual base salary
for 2017 and cash performance bonus for 2016 for the following
principal executive officer:
| Name and Current Position | Salary | Salary | ||
| Increase | Increase | Base | Cash | |
| (%) | ($) | Salary | Bonus | |
|
John A. Scarlett, M.D., President, Chief Executive Officer and Director |
3.5% | $21,800 | $644,000 | $373,300 |
1
About GERON CORPORATION (NASDAQ:GERN)
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. GERON CORPORATION (NASDAQ:GERN) Recent Trading Information
GERON CORPORATION (NASDAQ:GERN) closed its last trading session up +0.03 at 2.18 with 1,312,349 shares trading hands.
